ADHD

Poulton led a meta-analysis of past methylphenidate dosing to encourage greater investigation in the future.

Recommended dosage varies, but effectiveness increases with dosage, necessitating conclusive research.

From 2010 to 2017, there was an increase of over 30% in the number of commercially insured children being diagnosed with ADHD.

The FDA approved the Monarch electronic Trigeminal Nerve Stimulation based on the findings of a trial involving children aged 7-12 years old.

Just 2 hours of screen time can lead to children being 7 times more likely to develop attention deficit/hyperactivity disorder and 5 times more likely to report clinically significant externalizing problems.

A fourth phase 3 study of investigational drug SPN-812 demonstrated a significant decrease in ADHD-RS-5 scores compared to placebo.

The prevalence of anxiety, depression, and ADD was higher in patients with this excessive sweating disorder than the general population.

The CNS stimulant was approved as an extended-released capsule intended to serve as a first-line ADHD therapy.

A pilot study testing a multi-tasking game in children with autism and ADHD demonstrated feasibility, acceptability, and non-significant efficacy.

Prenatal exposure to the antiepileptic drug valproate is associated with increased risk for ADHD independent of its link to congenital malformations.

MD Magazine's most popular stories this year ranged from new clinical insights, to physician-submitted columns, to perspectives on burnout in the workplace.

A paternal smoking amount of more than 15 cigarettes per day was significantly associated with children's ADHD.

The novel methylphenidate formulation indicated for evening administration in patients with ADHD aged 6 years and older has shown improvement in the severity of ADHD symptoms in the early morning and throughout the day for patients.

The combined results of a recent meta-analysis and a new population-based study supports there being a significant association between asthma and ADHD.

Children born early preterm (gestational age 22-33 weeks) scored an average of 0.24 SD higher than children born full term. For girls, this increased to 0.8 SD higher than term born sisters.

Firstborn children with ≥2 younger siblings have a 1.71 times higher risk of developing ADHD compared to children without siblings.

The authors found no studies supporting the use of alternative treatments, such as cognitive behavioral therapy or omega fatty acids, over ADHD medications.

Children with conditions such as ADHD could be put at greater risk of obesity or type 2 diabetes due to antipsychotic prescriptions.

An amphetamine salts mixture (SHP465) showed efficacy in improving problem solving and sustaining attention in ADHD adults.

The prevalence of HDP and neurodevelopmental disorders are associated with increased risks up to 70%, according to the systematic review and meta-analysis.

Factors influencing long-term ADHD medication continuity include child acceptance of treatment and parent-perceived need for and concerns about ADHD medication at 3 months.

The findings revealed a striking gender difference with boys, as the lead-ADHD association was significantly stronger, equating to a 149% increased risk.

Researchers in Baltimore found a connection between prenatal complications, genetic risk, and the impact on neurodevelopmental conditions in children.

The new findings also show that the premature activation of synapses can be prevented by AMPA receptor antagonist therapy.

Poison Control Centers get roughly 200 calls each week related to children and adolescents under the age of 19 being exposed to medications intended for attention-deficit hyperactivity disorder.